Cargando…

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carter, Corey A., Oronsky, Bryan T., Caroen, Scott Z., Scicinski, Jan J., Degesys, Aiste, Kim, Michelle M., Oronsky, Arnold L., Lybeck, Harry, Cabrales, Pedro, Oronsky, Neil, Reid, Tony, Roswarski, Joseph, Brzezniak, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2016
Materias:	Published online: March, 2016
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821137/ https://www.ncbi.nlm.nih.gov/pubmed/27065849 http://dx.doi.org/10.1159/000444631

Ejemplares similares

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets
por: Carter, Corey A., et al.
Publicado: (2016)

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization
por: Carter, Corey A., et al.
Publicado: (2016)

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001
por: Carter, Corey A., et al.
Publicado: (2016)

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor
por: Carter, Corey A., et al.
Publicado: (2015)

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report
por: Brzezniak, Christina, et al.
Publicado: (2016)

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC
por: Carter, Corey A., et al.
Publicado: (2016)

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet
por: Cottrill, Hope, et al.
Publicado: (2018)

RRx-001, A novel dinitroazetidine radiosensitizer
por: Oronsky, Bryan, et al.
Publicado: (2016)

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells
por: Oronsky, Bryan, et al.
Publicado: (2018)

Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic Syndrome?
por: Carter, Corey A., et al.
Publicado: (2016)

The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis
por: Carter, Corey A., et al.
Publicado: (2016)

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001
por: Oronsky, Bryan, et al.
Publicado: (2016)

Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients
por: Reid, T., et al.
Publicado: (2014)

Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx‐001
por: Oronsky, Bryan, et al.
Publicado: (2018)

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors
por: Oronsky, Bryan, et al.
Publicado: (2016)

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor
por: Brzezniak, Christina, et al.
Publicado: (2017)

Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19
por: Oronsky, Bryan., et al.
Publicado: (2020)

Complete metabolic response of metastatic castration‐resistant neuroendocrine carcinoma of the prostate after treatment with RRx‐001 and reintroduced platinum doublets
por: Ojemuyiwa, Michelle, et al.
Publicado: (2018)

RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"
por: Oronsky, Bryan, et al.
Publicado: (2020)

RRx-001 Increases Erythrocyte Preferential Adhesion to the Tumor Vasculature
por: Jani, Vinay P., et al.
Publicado: (2021)

Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)
por: Reid, Tony, et al.
Publicado: (2023)

RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist
por: Oronsky, Bryan, et al.
Publicado: (2023)

From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria
por: Yalcin, Ozlem, et al.
Publicado: (2015)

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma
por: Fine, Howard, et al.
Publicado: (2023)

Superficial Venous-Associated Inflammation from Direct IV Administration of RRx-001 in Rats
por: Caroen, Scott, et al.
Publicado: (2022)

Dysphonia after Bevacizumab Rechallenge: A Case Report
por: Carter, Corey A., et al.
Publicado: (2015)

Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity
por: Zhao, Hongjuan, et al.
Publicado: (2015)

Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors
por: Raghunand, Natarajan, et al.
Publicado: (2017)

Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management
por: Oronsky, Bryan, et al.
Publicado: (2017)

No patient left behind: The promise of immune priming with epigenetic agents
por: Carter, Corey A., et al.
Publicado: (2017)

NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001()
por: Scicinski, Jan, et al.
Publicado: (2015)

Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001
por: Ning, Shoucheng, et al.
Publicado: (2015)

The War on Cancer: A Military Perspective
por: Oronsky, Bryan, et al.
Publicado: (2015)

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry
por: Zhao, Hongjuan, et al.
Publicado: (2017)

A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation
por: Jayabalan, Nanthini, et al.
Publicado: (2023)

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance
por: Oronsky, Bryan, et al.
Publicado: (2015)

Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy
por: Oronsky, Bryan, et al.
Publicado: (2016)

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis
por: Oronsky, Bryan, et al.
Publicado: (2018)

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents
por: Oronsky, Bryan, et al.
Publicado: (2016)

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial()(): A TITE-CRM Phase I/II Clinical Trial
por: Kim, Michelle M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0uf86acv7nsj0oa1uu302fquaa